Ashutosh Lal, MD
Pediatric Hematology-Oncology · Oakland, CANPI 1023048469
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.7%), education and travel and lodging — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Vertex at 35.3% of the total. Reporting peaked in 2023 at $7,360 and has fallen 99.7% since, to $25 in 2025.
Across 23 payments — averaging $906.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$7K
- E.r. Squibb & Sons, L.L.C.$7K
- Chiesi USA, Inc.$6K
- Novartis$600
- Agios Pharmaceuticals, Inc.$140
- Genetix Biotherapeutics Inc$25
Across 61 payments — averaging $19,982 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Agios Pharmaceuticals, Inc.$458K
- La Jolla Pharmaceutical Company$419K
- Bristol Myers Squibb$303K
- Terumo BCT, Inc.$38K
What the payments were for
- Consulting fees$10,35050%
- Grants$6003%
- Travel & lodging$2,19711%
- Food & beverage$5813%
- Education$7,11434%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 9 | $7,360 |
| E.r. Squibb & Sons, L.L.C. | 1 | $7,114 |
| Chiesi USA, Inc. | 10 | $5,603 |
| Novartis | 1 | $600 |
| Agios Pharmaceuticals, Inc. | 1 | $140 |
| Genetix Biotherapeutics Inc | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,842 in reported general payments places this provider in the 80th percentile of 307 pediatric hematology-oncology providers in California.
See all pediatric hematology-oncology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pediatric hematology-oncology in Oakland
- Caroline HastingsOakland$127K
- Elliott VichinskyOakland$73K
- Mark WaltersOakland$69K
- Anurag AgrawalOakland$17K
- Philip PizzoPalo Alto$2.6M
- Vinod BalasaMadera$508K
- Akshat JainRedlands$447K
- Noah FedermanLos Angeles$399K
- Vanessa Salinas-LunaOrange$344K
- Daniel KraftStanford$294K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.